BR112013000941A2 - formulações de 14-epi-análogos de vitamina d - Google Patents

formulações de 14-epi-análogos de vitamina d

Info

Publication number
BR112013000941A2
BR112013000941A2 BR112013000941A BR112013000941A BR112013000941A2 BR 112013000941 A2 BR112013000941 A2 BR 112013000941A2 BR 112013000941 A BR112013000941 A BR 112013000941A BR 112013000941 A BR112013000941 A BR 112013000941A BR 112013000941 A2 BR112013000941 A2 BR 112013000941A2
Authority
BR
Brazil
Prior art keywords
epi
vitamin
analog formulations
formulations
analog
Prior art date
Application number
BR112013000941A
Other languages
English (en)
Inventor
Delansorne Rémi
Original Assignee
Hybrigenics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/836,974 external-priority patent/US20120015913A1/en
Priority claimed from EP10305783A external-priority patent/EP2407152A1/en
Application filed by Hybrigenics Sa filed Critical Hybrigenics Sa
Publication of BR112013000941A2 publication Critical patent/BR112013000941A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

formulações de 14-epi-análogo de vitamina d". a presente invenção fornece novas formulações de 14-epi-análogos de vitamina d, tal como inecalcitol, fornecendo perfil de absorção melhorado.
BR112013000941A 2010-07-15 2011-07-13 formulações de 14-epi-análogos de vitamina d BR112013000941A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/836,974 US20120015913A1 (en) 2010-07-15 2010-07-15 Formulations of 14-EPI-Analogues of Vitamin D
EP10305783A EP2407152A1 (en) 2010-07-15 2010-07-15 Formulations of 14-epi-analogues of vitamin D
PCT/EP2011/061984 WO2012007517A1 (en) 2010-07-15 2011-07-13 Formulations of 14 - epi -analogues of vitamin d

Publications (1)

Publication Number Publication Date
BR112013000941A2 true BR112013000941A2 (pt) 2017-10-31

Family

ID=44281019

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112013000941A BR112013000941A2 (pt) 2010-07-15 2011-07-13 formulações de 14-epi-análogos de vitamina d
BR112013000930A BR112013000930A2 (pt) 2010-07-15 2011-07-13 formulações de 14-epi-análogos de vitamina d e cmc

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112013000930A BR112013000930A2 (pt) 2010-07-15 2011-07-13 formulações de 14-epi-análogos de vitamina d e cmc

Country Status (18)

Country Link
EP (2) EP2407154B1 (pt)
JP (2) JP5836373B2 (pt)
KR (2) KR101821441B1 (pt)
CN (2) CN103096877B (pt)
AU (2) AU2011278352B2 (pt)
BR (2) BR112013000941A2 (pt)
CA (2) CA2805203A1 (pt)
DK (2) DK2407155T3 (pt)
ES (2) ES2398640T3 (pt)
HR (2) HRP20130093T1 (pt)
IL (2) IL224191A (pt)
MX (1) MX2013000539A (pt)
NZ (2) NZ606678A (pt)
PL (2) PL2407155T3 (pt)
PT (2) PT2407154E (pt)
SG (2) SG187072A1 (pt)
SI (2) SI2407154T1 (pt)
WO (3) WO2012007512A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120015913A1 (en) 2010-07-15 2012-01-19 Delansorne Remi Formulations of 14-EPI-Analogues of Vitamin D
PL2407155T3 (pl) * 2010-07-15 2013-05-31 Hybrigenics Sa Formulacje inekalcytolu
EP2908827A4 (en) * 2012-10-19 2016-08-31 Celus Pharmaceuticals Inc VITAMIN D ANALOGUE FOR THE TREATMENT OF A NEUROLOGICAL DISEASE
KR20190017873A (ko) * 2016-06-08 2019-02-20 썬리겐 헬쓰케어 아게 홀수의 탄소 원자를 갖는 지질 및 제약 조성물 또는 영양 보충제로서의 그의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2166898C (en) 1993-07-09 2004-09-07 Roger Bouillon Novel structural analogues of vitamin d
JPH10111593A (ja) * 1996-10-04 1998-04-28 Asahi Optical Co Ltd 複写機の変倍光学装置
US5936105A (en) 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
GB0305332D0 (en) 2003-03-10 2003-04-09 Leuven K U Res & Dev Biological evaluation of novel vitamin D analogues
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US7332482B2 (en) 2003-09-24 2008-02-19 Bioxell S.P.A. Method for treating benign prostatic hyperplasia
GB0423091D0 (en) * 2004-10-19 2004-11-17 Leuven K U Res & Dev Bioactive vitamin d analogues
US20070093458A1 (en) * 2005-07-18 2007-04-26 Anchel Schwartz Preparation of paricalcitol and crystalline forms thereof
US20080145411A1 (en) * 2006-10-06 2008-06-19 Kaneka Corporation Composition of high absorbability for oral administration comprising oxidized coenzyme q10
JP2010111593A (ja) * 2008-11-04 2010-05-20 Teijin Pharma Ltd １４−エピ−１９−ノルプレビタミンｄ３誘導体
CN102448466A (zh) * 2009-05-20 2012-05-09 混合基因股份公司 伊奈骨化醇的新治疗应用
PL2407155T3 (pl) * 2010-07-15 2013-05-31 Hybrigenics Sa Formulacje inekalcytolu

Also Published As

Publication number Publication date
SG187072A1 (en) 2013-03-28
JP2013531024A (ja) 2013-08-01
AU2011278346B2 (en) 2016-04-07
WO2012007570A2 (en) 2012-01-19
AU2011278352B2 (en) 2016-07-21
CN103096876A (zh) 2013-05-08
IL224191A (en) 2016-03-31
RU2013106493A (ru) 2014-08-20
WO2012007517A1 (en) 2012-01-19
HRP20130237T1 (hr) 2013-04-30
CN103096877B (zh) 2017-09-22
AU2011278352A1 (en) 2013-03-07
IL224192A (en) 2016-02-29
EP2407154A1 (en) 2012-01-18
KR101821441B1 (ko) 2018-01-23
CA2805203A1 (en) 2012-01-19
DK2407154T3 (da) 2013-03-04
PT2407154E (pt) 2013-02-15
PL2407154T3 (pl) 2013-04-30
KR20130089249A (ko) 2013-08-09
EP2407155B1 (en) 2012-12-26
MX2013000539A (es) 2013-04-11
EP2407155A1 (en) 2012-01-18
KR101821440B1 (ko) 2018-01-23
EP2407154B1 (en) 2012-11-07
WO2012007570A3 (en) 2012-05-24
JP2013531023A (ja) 2013-08-01
DK2407155T3 (da) 2013-04-02
SG187071A1 (en) 2013-02-28
CA2805198C (en) 2018-07-31
AU2011278346A1 (en) 2013-03-07
HRP20130093T1 (hr) 2013-02-28
CN103096877A (zh) 2013-05-08
PL2407155T3 (pl) 2013-05-31
RU2013106492A (ru) 2014-08-20
CA2805198A1 (en) 2012-01-19
JP5836373B2 (ja) 2015-12-24
NZ606678A (en) 2014-11-28
KR20130103709A (ko) 2013-09-24
NZ606679A (en) 2014-07-25
PT2407155E (pt) 2013-04-03
JP5836372B2 (ja) 2015-12-24
ES2401715T3 (es) 2013-04-23
WO2012007512A1 (en) 2012-01-19
BR112013000930A2 (pt) 2017-10-31
SI2407155T1 (sl) 2013-04-30
SI2407154T1 (sl) 2013-03-29
ES2398640T3 (es) 2013-03-20

Similar Documents

Publication Publication Date Title
PH12015500263A1 (en) New bicyclic derivatives
IN2014DN09346A (pt)
UY34587A (es) Formulaciones estabilizadas que contienen anticuerpos antiang2
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
MX345514B (es) Composiciones pesticidas.
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
UY34817A (es) Tienopirimidinas
CR20130539A (es) Triazolopiridinas
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
JO3755B1 (ar) تركيبات تستوستيرون
BR112013016679A2 (pt) formulações de vitamina e em pó aperfeiçoadas
BR112012026542A2 (pt) abordagem seletiva de tecido
BR112013000941A2 (pt) formulações de 14-epi-análogos de vitamina d
CO6761388A2 (es) Composiciones pharmaceuticas que comprenden alisporivir
CR20140531A (es) Derivados de ariletinilo
IN2015DN02643A (pt)
IN2015DN02645A (pt)
TR201007106A1 (tr) Sefpodoksim proksetil formülasyonları.
TR201002878A2 (tr) Sefpodoksim proksetil içeren farmasötik bileşimler.
CR20150028A (es) Derivados de ariletinilo
MX2013008559A (es) Derivados de leptina.
IN2015DN02648A (pt)
IN2015DN02644A (pt)
MY151659A (en) Photopolymerizable Resin Composition

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal: dismissal of application maintained